Collegium pharmaceutical, inc. (COLL)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues
Product revenues, net

298,696

296,701

295,925

293,159

291,180

280,413

217,780

159,554

90,053

28,476

18,985

7,443

0

0

0

-

-

-

-

-

-

-

-

-

-

Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible asset amortization

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of products revenues

182,020

193,660

174,298

173,551

171,735

165,677

137,045

91,591

45,330

2,595

1,685

1,161

0

0

0

-

-

-

-

-

-

-

-

-

-

Gross profit

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development

10,014

10,340

10,191

9,607

9,385

8,661

8,606

8,768

8,710

8,572

9,709

10,894

13,016

14,948

13,148

13,252

10,592

7,975

8,751

11,211

13,135

14,959

0

0

0

Selling, general and administrative

115,357

116,449

121,810

125,186

127,530

126,760

121,398

110,708

101,491

92,756

93,034

93,843

91,954

80,632

63,171

45,511

28,272

18,932

12,046

6,826

4,415

2,706

0

0

0

Total costs and expenses

269,867

271,285

257,135

259,180

259,486

301,098

267,049

211,067

155,531

103,923

104,428

105,898

105,554

95,793

76,348

58,763

38,864

26,907

20,797

18,037

17,550

17,665

0

0

0

Income (loss) from operations

-8,695

-23,748

-10,374

-15,185

-17,470

-20,685

-49,269

-51,513

-65,478

-75,447

-85,443

-98,455

-101,671

-94,082

-75,940

-58,763

-38,864

-26,907

-20,797

-18,037

-17,550

-17,665

0

0

0

Interest expense

5,498

909

3,102

8,742

14,664

20,130

0

0

0

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

Interest income

1,621

1,935

2,041

2,099

1,958

1,687

1,378

993

739

582

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Gain on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

91

0

0

0

-

-

-

-

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-94

-202

-297

-350

-348

-402

-356

-286

-252

0

0

0

Net income (loss)

-12,572

-22,722

-11,435

-21,828

-30,176

-39,128

-65,617

-62,378

-70,439

-74,865

-85,021

-98,202

-101,601

-94,176

-76,142

-59,060

-39,214

-27,255

-21,199

-18,393

-17,836

-17,917

0

0

0

Loss per share - basic and diluted

-

-0.07

-0.18

-0.14

-

-

-

-

-

-0.54

-0.45

-0.72

-0.79

-1.02

-1.13

-1.05

-0.68

-

-0.46

-0.45

-

-4.50

-7.85

-5.33

-5.03

Weighted-average shares - basic and diluted (in shares)

-

33,600

33,481

33,397

-

-

-

-

-

32,485

29,753

29,441

29,350

27,100

23,460

23,417

23,130

-

20,531

11,791

-

955

940

926

912

Earnings (loss) per share - basic (in dollars per share)

0.01

-

-

-

-0.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.34

-

-

-

-

Weighted-average shares - basic (in shares)

34,100

-

-

-

33,331

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,001

-

-

-

-

Earnings (loss) per share - diluted (in dollars per share)

0.01

-

-

-

-0.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.65

-

-

-

-

Weighted-average shares - diluted (in shares)

35,069

-

-

-

33,331

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,554

-

-

-

-